Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase Family: Novel Prognostic Biomarkers and Tumor Microenvironment Regulators for Lower-Grade Glioma

Lower-grade glioma (LGG) is a group of tumors arising from the cells of the central nervous system. Although various therapy interventions are used, the prognosis remains different. Novel biomarkers are needed for the prognosis of disease and novel therapeutic strategies in LGG. The procollagen-lysi...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular neuroscience 2022-02, Vol.16, p.838548-838548
Main Authors: Gong, Siming, Wu, Changwu, Köhler, Franziska, Meixensberger, Jürgen, Schopow, Nikolas, Kallendrusch, Sonja
Format: Article
Language:English
Subjects:
Biomarkers
Brain tumors
Cancer
Cellular Neuroscience
Central nervous system
Collagen
Datasets
Disease
Gene expression
Genomes
Glioma
immune infiltration
Immunology
immunotherapy
Ketoglutaric acid
lower-grade glioma
Lysine
Medical prognosis
Metastases
Patients
PLOD family
Procollagen
Procollagen-lysine 5-dioxygenase
Prognosis
Proteins
Software
Survival analysis
Tumor microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lower-grade glioma (LGG) is a group of tumors arising from the cells of the central nervous system. Although various therapy interventions are used, the prognosis remains different. Novel biomarkers are needed for the prognosis of disease and novel therapeutic strategies in LGG. The procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) family contains three members and is related to multiple cancers, yet it was not investigated in LGG. Data from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) cohorts were used to analyze the role of PLOD in LGG. As the PLOD family is involved in processes, such as tumor formation and cancer metastasis, we focused on its relationship to the tumor microenvironment (TME) in LGG. A high expression of the PLOD family relates to poor prognosis and high infiltration of immune cells within the TME. The expression level of the PLOD family might become a novel biomarker for prognosis and is a potential target for individual treatment decisions in LGG.
ISSN:1662-5102
1662-5102
DOI:10.3389/fncel.2022.838548